Purple Biotech Ltd. Sponsored ADR PPBT
1.49
0.01
0.68%
as of 25 Sep
- Market cap
- $2.4M
- P/E
- 0.0×
Follow PPBT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| ROE | (110.67%) | (122.85%) | (123.97%) | (10.44%) |
+8 more TTM periods Free account |
| ROA | (100.91%) | (104.05%) | (96.63%) | (8.77%) | |
| ROIC | (290.25%) | (546.31%) | (20,189.71%) | (13.86%) | |
| Return on Tangible Assets | (497.62%) | (1,129.79%) | (1,179.53%) | (67.18%) | |
| Average Days of Receivables | — | — | — | — | |
| Free Cash Flow per Share | (7.15) | (7.31) | (11.79) | (14.48) | |
| Free Cash Flow | (7.76) | (6.80) | (5.66) | (6.60) | |
| Capital Expenditures | (0.01) | — | 0.00 | 0.01 | |
| Other line items | |||||
| Cash ROIC | (42.35%) | (42.26%) | (29.41%) | (15.26%) | |
| Accounts Payable Turnover | 0.00 | 0.00 | 0.00 | 0.00 | |
| Average Days of Payables | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | |
| Research and Development Expense of Revenue | 0.00% | 0.00% | 0.00% | 0.00% | |
| Selling, General and Administrative Expense of Revenue | 0.00% | 0.00% | 0.00% | 0.00% | |
| Share Based Compensation of Revenue | 0.00% | 0.00% | 0.00% | 0.00% | |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating CF/Net income | 0.32 | 0.26 | 0.21 | 2.03 | |
| Depreciation/Fixed assets | 2.14 | 1.91 | 1.64 | 1.56 | |
| Capex/Depreciation | (0.02) | 0.00 | (0.01) | 0.04 | |
| Revenue per Share | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating CF per Share | (7.14) | (7.31) | (11.78) | (14.50) | |
| Capex per Share | (0.01) | 0.00 | (0.01) | 0.02 | |
| Capex to Sales | 0.00 | — | 0.00 | 0.00 | |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates